Carol Satler

1.2k total citations
19 papers, 859 citations indexed

About

Carol Satler is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carol Satler has authored 19 papers receiving a total of 859 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 10 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carol Satler's work include Cardiac electrophysiology and arrhythmias (8 papers), Ion channel regulation and function (6 papers) and Cardiomyopathy and Myosin Studies (5 papers). Carol Satler is often cited by papers focused on Cardiac electrophysiology and arrhythmias (8 papers), Ion channel regulation and function (6 papers) and Cardiomyopathy and Myosin Studies (5 papers). Carol Satler collaborates with scholars based in United States, Germany and United Kingdom. Carol Satler's co-authors include J. Grifo, William C. Merrick, Richard D. Abramson, Barry London, Mark R. Vesely, Gail A. Robertson, Matthew C. Trudeau, Debra J. Gilbert, Neal G. Copeland and Kimberly P. Newton and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Neuron.

In The Last Decade

Carol Satler

18 papers receiving 845 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carol Satler United States 9 744 539 213 63 32 19 859
Chai‐Ann Ng Australia 17 763 1.0× 472 0.9× 201 0.9× 161 2.6× 41 984
Giorgia Valle Italy 13 633 0.9× 572 1.1× 165 0.8× 13 0.2× 16 946
Pauline Dan Canada 6 363 0.5× 320 0.6× 148 0.7× 8 0.1× 1 0.0× 12 466
K Mruk United States 8 302 0.4× 52 0.1× 75 0.4× 23 0.4× 21 451
Tongbin Wu United States 11 720 1.0× 134 0.2× 23 0.1× 11 0.2× 15 821
Patana Teng-umnuay United States 7 379 0.5× 36 0.1× 121 0.6× 24 0.4× 7 413
Redwan Huq United States 13 391 0.5× 56 0.1× 60 0.3× 22 0.3× 17 525
Ghislaine Dell United Kingdom 7 341 0.5× 76 0.1× 47 0.2× 14 0.2× 8 416
Krishna Midde United States 14 385 0.5× 35 0.1× 40 0.2× 51 0.8× 1 0.0× 28 543
Leonne E. Philippen United States 8 281 0.4× 216 0.4× 24 0.1× 7 0.1× 8 369

Countries citing papers authored by Carol Satler

Since Specialization
Citations

This map shows the geographic impact of Carol Satler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Satler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Satler more than expected).

Fields of papers citing papers by Carol Satler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Satler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Satler. The network helps show where Carol Satler may publish in the future.

Co-authorship network of co-authors of Carol Satler

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Satler. A scholar is included among the top collaborators of Carol Satler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Satler. Carol Satler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Xu, Zefeng, Ping Wang, Jie Cao, et al.. (2025). Biomarker Analysis Reveals Antifibrotic and Anti-inflammatory Signatures in Idiopathic Pulmonary Fibrosis Patients Treated With INS018_055, an AI-discovered TNIK Inhibitor, in a 12-week Phase 2a Study. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A5354–A5354. 1 indexed citations
3.
Benza, Raymond L., Verónica Franco, Mandar A. Aras, et al.. (2022). Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design. Respiratory Research. 23(1). 355–355. 5 indexed citations
4.
Rosenkranz, Stephan, Jeremy Feldman, Vallerie V. McLaughlin, et al.. (2021). Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 10(1). 35–46. 27 indexed citations
5.
Cossú, Sergio F., Jacek Wilczek, Béla Merkely, et al.. (2017). Abstract 15415: TEMPO: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of Eleclazine on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator or Cardiac Resynchronization Therapy-Defibrillator. Circulation. 1 indexed citations
6.
Rosenkranz, Stephan, Jeremy Feldman, Vallerie V. McLaughlin, et al.. (2017). The ARROW Study: A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Selonsertib in Subjects with Pulmonary Arterial Hypertension. OA1983–OA1983. 6 indexed citations
7.
Tapson, Victor F., David Platt, Fang Xia, et al.. (2016). Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM Study. The American Journal of Medicine. 129(9). 978–985.e2. 43 indexed citations
8.
Heresi, Gustavo A., et al.. (2015). Incremental burden of group 3 Pulmonary Hypertension patients to U.S. payer. Value in Health. 18(3). A253–A253. 1 indexed citations
9.
10.
Singh, Steven, et al.. (1998). Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: a multicenter study. Journal of the American College of Cardiology. 31. 369–370. 6 indexed citations
11.
Satler, Carol, Mark R. Vesely, Priya Duggal, Geoffrey S. Ginsburg, & Alan H. Beggs. (1998). Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome. Human Genetics. 102(3). 265–272. 50 indexed citations
12.
London, Barry, Matthew C. Trudeau, Kimberly P. Newton, et al.. (1997). Two Isoforms of the MouseEther-a-go-go–Related Gene Coassemble to Form Channels With Properties Similar to the Rapidly Activating Component of the Cardiac Delayed Rectifier K+Current. Circulation Research. 81(5). 870–878. 238 indexed citations
13.
Satler, Carol, et al.. (1996). Novel missense mutation in the cyclic nucleotide‐binding domain of HERG causes long QT syndrome. American Journal of Medical Genetics. 65(1). 27–35. 1 indexed citations
14.
Satler, Carol, et al.. (1996). Novel missense mutation in the cyclic nucleotide-binding domain ofHERG causes long QT syndrome. American Journal of Medical Genetics. 65(1). 27–35. 48 indexed citations
15.
MacRae, Calum A., Mark R. Vesely, Edward P. Walsh, et al.. (1996). Missense Mutation in the Pore Region of HERG Causes Familial Long QT Syndrome. Circulation. 93(10). 1791–1795. 63 indexed citations
16.
Breitbart, Roger E., Barry London, Hanh T. Nguyen, & Carol Satler. (1995). Recent advances in the Laboratory of Molecular and Cellular Cardiology. The Annals of Thoracic Surgery. 60(6 Suppl). S509–S512. 1 indexed citations
17.
Towbin, Jeffrey A., R.T. Taggart, Michael H. Lehmann, et al.. (1994). Evidence of genetic heterogeneity in Romano-Ward long QT syndrome. Analysis of 23 families.. Circulation. 90(6). 2635–2644. 57 indexed citations
18.
19.
Grifo, J., Richard D. Abramson, Carol Satler, & William C. Merrick. (1984). RNA-stimulated ATPase activity of eukaryotic initiation factors.. Journal of Biological Chemistry. 259(13). 8648–8654. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chai‐Ann Ng Breakdown of academic impact, for papers by Giorgia Valle Breakdown of academic impact, for papers by Pauline Dan Breakdown of academic impact, for papers by K Mruk Breakdown of academic impact, for papers by Tongbin Wu Breakdown of academic impact, for papers by Patana Teng-umnuay Breakdown of academic impact, for papers by Redwan Huq Breakdown of academic impact, for papers by Ghislaine Dell Breakdown of academic impact, for papers by Krishna Midde Breakdown of academic impact, for papers by Leonne E. Philippen
Rankless by CCL
2026